<?xml version="1.0" encoding="UTF-8"?>
<funding-group>
 <award-group>
  <funding-source>Eisai Co., Ltd</funding-source>
 </award-group>
 <award-group>
  <funding-source>Kyowa Hakko Kirin Co., Ltd</funding-source>
 </award-group>
 <award-group>
  <funding-source>Zenyaku Kogyo Co., Ltd</funding-source>
 </award-group>
 <award-group>
  <funding-source>Chugai Pharmaceutical Co., Ltd</funding-source>
 </award-group>
 <award-group>
  <funding-source>Pfizer Japan Inc</funding-source>
 </award-group>
 <award-group>
  <funding-source>Janssen Pharmaceutical K.K.</funding-source>
 </award-group>
 <award-group>
  <funding-source>GlaxoSmithKline K.K.</funding-source>
 </award-group>
 <award-group>
  <funding-source>MSD K.K.</funding-source>
 </award-group>
 <award-group>
  <funding-source>AstraZeneca K.K.</funding-source>
 </award-group>
 <award-group>
  <funding-source>Takeda Pharmaceutical Company Limited</funding-source>
 </award-group>
 <award-group>
  <funding-source>Symbio Pharmaceuticals Limited</funding-source>
 </award-group>
 <award-group>
  <funding-source>Solasia Pharma K.K.</funding-source>
 </award-group>
 <award-group>
  <funding-source>Mundipharma K.K.</funding-source>
 </award-group>
 <award-group>
  <funding-source>Celgene K.K.</funding-source>
 </award-group>
 <award-group>
  <funding-source>Sumitomo Dainippon Pharma Co., Ltd</funding-source>
 </award-group>
 <award-group>
  <funding-source>HUYA Bioscience International</funding-source>
 </award-group>
</funding-group>
